FaZe Holdings, AXT And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining more than 700 points on Tuesday. Here are some big stocks recording losses in today’s session.
Needham Maintains Buy on KalVista Pharma, Lowers Price Target to $24
Needham analyst Serge Belanger maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target from $38 to $24.
US Stocks Open Higher As Dow Jumps 550 Points
U.S. stocks traded higher this morning, with the Dow Jones climbing more than 550 points on Tuesday.
Why Kalvista Pharmaceuticals Shares Are Down Over 50%
Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares are trading lower by 52.42% to $6.78 Tuesday morning after the company announced it terminated the KOMPLETE phase 2 clinical trial for KVD824 for the prevention of attacks in people with hereditary angioedema.
What Else?
KalVista Shares Plunge After Ending KVD824 HAE Trial Over Elevated Liver Enzymes In Patients
KalVista Pharmaceuticals Inc (NASDAQ:KALV) has terminated the KOMPLETE phase 2 trial for KVD824 to prevent attacks in people with hereditary angioedema…
KalVista Pharmaceuticals Announces Termination Of KVD824 Phase 2 KOMPLETE Trial For Prophylactic Treatment Of Hereditary Angioedema
- Safety signals observed will not yield targeted product profile –
- No impact on Sebetralstat expected safety profile or Phase 3 KONFIDENT trial –
- Oral Factor XIIa program to become primary
Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck‘s (NYSE:MRK) lead asset MK-2060…
KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off
KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the KONFIDENT-S open label extension (OLE) study for its ongoing Phase 3 study of sebetralstat for the on-demand treatment of hereditary angioedema (HAE) attacks.
SVB Leerink Maintains Outperform on KalVista Pharmaceuticals, Lowers Price Target to $45
SVB Leerink analyst Joseph Schwartz maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Outperform and lowers the price target from $51 to $45.
Needham Maintains Buy on KalVista Pharmaceuticals, Lowers Price Target to $38
Needham analyst Serge Belanger maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy and lowers the price target from $42 to $38.